Meta-analysis on risk of bleeding with apixaban in patients with renal impairment.

@article{Pathak2015MetaanalysisOR,
  title={Meta-analysis on risk of bleeding with apixaban in patients with renal impairment.},
  author={Ranjan Pathak and Anil Pandit and Paras Karmacharya and Madan Raj Aryal and Sushil Ghimire and Dilli Ram Poudel and Fadi Elias Shamoun},
  journal={The American journal of cardiology},
  year={2015},
  volume={115 3},
  pages={323-7}
}
Apixaban is a novel oral anticoagulant which is approved for the management of atrial fibrillation and venous thromboembolism prophylaxis. There have been concerns regarding bleeding risks with apixaban in patients with renal impairment. We performed a systematic review and meta-analysis to evaluate the risk of bleeding with apixaban in these patients. Relevant studies were identified through electronic literature searches of MEDLINE, EMBASE, Cochrane library, and clinicaltrials.gov (from… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 12 extracted citations

Direct oral anticoagulants: a practical guide for the emergency physician.

European journal of emergency medicine : official journal of the European Society for Emergency Medicine • 2016

Similar Papers

Loading similar papers…